Hepatitis, Viral, Human  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

63 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
NCT01459913 / 2011-001323-21: Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Checkmark HepDART 2013: CONCISE
Dec 2013 - Dec 2013: HepDART 2013: CONCISE
Checkmark EASL 2013: CONCIZE
Apr 2013 - Apr 2013: EASL 2013: CONCIZE
Terminated
3b
239
US, Canada, Europe, RoW
Telaprevir, INCIVEK, INCIVO, VX-950, Pegylated Interferon Alfa-2a, Pegasys, Peg-IFN-Alfa-2a, Ribavirin, Copegus, RBV
Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
01/14
01/14
NCT00048945: Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Completed
3
820
US, Canada, Europe, RoW
PEGASYS
Hoffmann-La Roche
Chronic Hepatitis B
10/04
10/04
NCT00038974: Hepatitis C Antiviral Resistance in African-Americans

Completed
3
401
US
peginterferon alfa-2a, Ribavirin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), Hoffmann-La Roche
Hepatitis C
12/04
11/05
NCT00221286: Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Terminated
3
2
Europe
pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy
University Hospital, Bonn, Hoffmann-La Roche
Chronic Hepatitis B, HIV Infections
01/07
01/07
NCT02806505: HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

Completed
3
81
Europe, RoW
Peginterferon alfa-2a, Pegasys
Hoffmann-La Roche
Hepatitis C, Chronic
08/07
08/07
NCT00081770: Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Completed
3
4469
NA
PegIntron (peginterferon alfa-2b; SCH 54031), PegIntron, REBETOL (ribavirin; SCH 18908), REBETOL [the Schering-Plough brand name for ribavirin], PEGASYS (peginterferon alfa-2a), PEGASYS, COPEGUS (ribavirin), COPEGUS [the Hoffman-La Roche brand name for ribavirin]
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
11/07
11/07
NCT01178996 / 2004-001277-25: Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Completed
3
552
Europe
Thymosin alpha 1, Zadaxin, Ribavirin, Copegus, PEGinterferon alfa2a, Pegasys, Placebo
sigma-tau i.f.r. S.p.A., SciClone Pharmaceuticals
Chronic Hepatitis C
05/08
07/09
NCT02791256: A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

Terminated
3
23
Europe
Ribavirin, Copegus, Ro 20-9963, peginterferon alfa-2a, Pegasys, Ro 25-8310
Hoffmann-La Roche
Hepatitis C, Chronic
06/08
06/08
NCT00441584: The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Terminated
3
117
NA
PegIntron (peginterferon alfa-2b), SCH 54031, PEG-Intron, PegIntron, ViraferonPeg, peginterferon alfa-2b, Rebetol (ribavirin), SCH 18908, Rebetol, REBETOL, ribavirin
Merck Sharp & Dohme LLC, Integrated Therapeutics Group
Hepatitis C, Chronic
06/08
06/08
CIPPAD, NCT00136318: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Completed
3
208
Europe
Escitalopram, Placebo, Peginterferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin
Charite University, Berlin, Germany
Depression
09/08
09/08
NCT02732639: A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Completed
3
31
Europe
Pegylated Interferon (PEG-IFN) alfa-2a, PEGASYS
Hoffmann-La Roche
Hepatitis D, Chronic
12/08
12/08
NCT00412750: Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

Terminated
3
159
US
Telbivudine (LdT), Sebivo, peginterferon alpha-2a, Pegasys
Novartis
Hepatitis B
02/09
02/09
NCT00122616: Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

Completed
3
52
Europe
Peginterferon alpha-2a (Pegasys®), Ribavirin, HIV antiretroviral therapy
French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche
HIV Infections, Hepatitis C, Chronic
03/09
03/09
NCT01237496 / 2005-000336-25: Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Completed
3
17
Europe
peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis B, Chronic
09/09
09/09
MASTER, NCT01296971: A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C

Withdrawn
3
0
RoW
peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
12/09
12/09
NCT01095835 / 2004-002985-39: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Completed
3
131
Europe
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegasys®, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM)
Hoffmann-La Roche
Hepatitis B, Chronic
01/10
01/10
NCT00483938: The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

Completed
3
236
US, Canada
Pegylated-interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
05/10
05/10
NCT00627926 / 2007-004720-20: A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Checkmark REALIZE & ADVANCE
Mar 2014 - Mar 2014: REALIZE & ADVANCE
Checkmark AASLD 2013: OPTIMIZE & ADVANCE HEOR data
Oct 2013 - Oct 2013: AASLD 2013: OPTIMIZE & ADVANCE HEOR data
Checkmark ADVANCE - HRQL data
More
Completed
3
1095
US, Canada, Europe, RoW
Pegylated Interferon Alfa 2a, Pegasys, Peg-IFN-alfa-2a, Telaprevir, VX-950, Ribavirin, Copegus, RBV, Placebo
Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited
Hepatitis C
05/10
05/10
NCT00703118: A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Checkmark REALIZE
Jun 2014 - Jun 2014: REALIZE
Checkmark EASL 2014: REALIZE & HEP3002
Mar 2014 - Mar 2014: EASL 2014: REALIZE & HEP3002
Checkmark REALIZE & ADVANCE
More
Completed
3
663
US, Canada, Europe, RoW
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Tibotec BVBA, Tibotec Pharmaceutical Limited
Hepatitis C, Chronic
07/10
07/10
NCT00845065 / 2008-004760-39: Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

Checkmark P3 data
Mar 2012 - Mar 2012: P3 data
Completed
3
202
NA
Boceprevir, SCH 503034, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, SCH 18908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
10/10
10/10
ADVANCE, NCT00661076: Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Completed
3
10
RoW
adefovir dipivoxil, peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis B, Chronic
05/11
05/11
NCT01853254: A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Completed
3
272
US, Europe, RoW
Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
09/11
09/11
NCT00800735 / 2008-002022-10: A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Completed
3
30
US, Canada, Europe
Pegylated-interferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin, Copegus, Ro 20-9963
Hoffmann-La Roche
Hepatitis C, Chronic
03/12
03/12
NCT01054573 / 2009-012613-21: VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Checkmark EASL 2013: VX-950-TiDP24-C219
Apr 2013 - Apr 2013: EASL 2013: VX-950-TiDP24-C219
Checkmark Data-AASLD
Nov 2011 - Nov 2011: Data-AASLD
Completed
3
90
US, Canada, Europe, RoW
Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
Janssen Infectious Diseases BVBA, Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
03/12
05/12
NCT00623428 / 2007-004993-15: A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Completed
3
235
US, Canada, Europe, RoW
peginterferon alfa-2a, Pegasys®, PEG-IFN alfa-2a, Ribavirin, Copegus®
Hoffmann-La Roche
Hepatitis C, Chronic
05/12
05/12
NCT01500772 / 2011-004653-31: Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Terminated
3
6
US, Canada, Europe
Alisporivir, DEB025, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®, RBV
Debiopharm International SA
Hepatitis C
05/12
05/12
NCT01290731: A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Checkmark CONCERTO-2 and CONCERTO-3
Mar 2014 - Mar 2014: CONCERTO-2 and CONCERTO-3
Checkmark APASL 2014: CONCERTO studies
Mar 2014 - Mar 2014: APASL 2014: CONCERTO studies
Checkmark CONCERTO studies
More
Completed
3
49
Japan
TMC435, Pegylated interferon (pegIFN alpha-2a), PEGASYS, Ribavirin (RBV), COPEGUS
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
08/12
08/12
NCT01288209: A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Checkmark CONCERTO-2 and CONCERTO-3
Mar 2014 - Mar 2014: CONCERTO-2 and CONCERTO-3
Checkmark APASL 2014: CONCERTO studies
Mar 2014 - Mar 2014: APASL 2014: CONCERTO studies
Checkmark CONCERTO studies
More
Completed
3
106
Japan
TMC435, Peginterferon alfa-2a (PegIFNα-2a ), PEGASYS, Ribavirin (RBV), COPEGUS
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
09/12
09/12
NCT01292239: A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Checkmark CONCERTO-1
Apr 2014 - Apr 2014: CONCERTO-1
Checkmark APASL 2014: CONCERTO studies
Mar 2014 - Mar 2014: APASL 2014: CONCERTO studies
Checkmark CONCERTO studies
More
Completed
3
183
Japan
Placebo, TMC435, Peginterferon alfa-2a (pegIFN alfa-2a), PEGASYS, Ribavirin (RBV), COPEGUS
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
10/12
10/12
NCT01892241: Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Completed
3
74
RoW
Pegasys(Roche), peginterferon alfa-2a, Entecavir
Third Affiliated Hospital, Sun Yat-Sen University
Antiviral Treatment of Chronic Hepatitis B
11/12
02/13
QUEST-1, NCT01289782 / 2010-020444-36: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark QUEST-1
Jun 2014 - Jun 2014: QUEST-1
Checkmark EASL 2014: QUEST 1 & QUEST 2
More
Completed
3
395
US, Canada, Europe, RoW
Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Pegasys, Ribavirin (RBV), Copegus
Janssen R&D Ireland
Hepatitis C
01/13
01/13
NCT01497366 / 2011-005055-14: Phase 3 Study of Sofosbuvir and Ribavirin

Checkmark DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Apr 2014 - Apr 2014: DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Checkmark EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
Mar 2014 - Mar 2014: EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
Checkmark EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
More
Completed
3
527
US, Canada, Europe, RoW
Sofosbuvir, Sovaldi™, GS-7977, PSI-7977, PEG, Pegasys®, RBV
Gilead Sciences
Hepatitis C
01/13
04/13
NEUTRINO, NCT01641640: Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Checkmark FUSION, NEUTRINO & VALENCE
Apr 2014 - Apr 2014: FUSION, NEUTRINO & VALENCE
Checkmark DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Apr 2014 - Apr 2014: DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Checkmark DDW 2014: FUSION & NEUTRINO
More
Completed
3
328
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, RBV, Ribasphere®, PEG, PEGASYS®
Gilead Sciences
Chronic Hepatitis C
01/13
04/13
PROMISE, NCT01281839 / 2010-021113-23: An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark BWG 2014: PROMISE
Aug 2014 - Aug 2014: BWG 2014: PROMISE
Checkmark BWG 2014: PROMISE
More
Completed
3
394
US, Canada, Europe, RoW
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Pegasys, Ribavirin (RBV), Copegus
Janssen R&D Ireland
Hepatitis C
02/13
02/13
QUEST-2, NCT01290679 / 2010-021174-11: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark QUEST-2
Jun 2014 - Jun 2014: QUEST-2
Checkmark EASL 2014: QUEST 1 & QUEST 2
More
Completed
3
393
US, Europe, RoW
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), PegIFNα-2a (Pegasys), PegIFNα-2b (PegIntron), Ribavirin (RBV), Copegus, Rebetol
Janssen R&D Ireland
Hepatitis C
02/13
02/13
VIRID, NCT00662220 / 2007-005344-25: High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4

Terminated
3
110
Europe
ribavirin, Copegus, Pegasys, NeoRecormon
Foundation for Liver Research, Hoffmann-La Roche
Chronic Hepatitis C
06/13
11/13
NCT01697501 / 2012-002777-56: A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253

Completed
3
88
Europe
Interleukin 28B testing
Hoffmann-La Roche
Hepatitis B, Chronic
06/13
06/13
NCT01479868: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Checkmark
Sep 2014 - Sep 2014: 
Checkmark CROI 2014
Mar 2014 - Mar 2014: CROI 2014
Checkmark Primary results of naïve/relapser HIV/HCV co-infected patients at EACS
More
Completed
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen R&D Ireland
Hepatitis C Virus Genotype-1
08/13
08/13
NCT01389323: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Completed
3
448
US
Daclatasvir, BMS-790052, Peg-Interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
09/13
01/14
Hallmark QUAD, NCT01573351 / 2011-005422-21: Phase III ASV+DCV+Peg+Rib (Nulls/Partials)

Completed
3
398
US, Canada, Europe, RoW
Asunaprevir, BMS-650032, Daclatasvir, BMS-790052, Peg-interferon Alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
09/13
12/13
NCT01448044 / 2011-002793-23: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Completed
3
152
US, Europe
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
10/13
01/14
NCT01581203 / 2011-005446-35: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Checkmark AVHC 2014
Oct 2014 - Oct 2014: AVHC 2014
Checkmark HALLMARK DUAL
Jul 2014 - Jul 2014: HALLMARK DUAL
Checkmark HALLMARK DUAL
More
Completed
3
748
US, Canada, Europe, RoW
Asunaprevir (ASV), BMS-650032, Daclatasvir (DCV), BMS-790052, Pegylated-interferon alfa 2a (PegIFN), Pegasys, Ribavirin (RBV), Copegus
Bristol-Myers Squibb
Hepatitis C Virus
10/13
09/14
COMMAND-3, NCT01492426 / 2011-004237-14: Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Checkmark VHC 2014: COMMAND-3
Oct 2014 - Oct 2014: VHC 2014: COMMAND-3
Completed
3
605
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Telaprevir, Incivek®, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C
12/13
03/14
NCT01467479 / 2011-002668-25: A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Terminated
3
185
US, Canada, Europe
Telaprevir, VX-950, Ribavirin, Copegus®, RBV, Pegylated Interferon Alfa-2a, Pegasys®, Peg-IFN-Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Vertex Pharmaceuticals Incorporated
Hepatitis C
02/14
02/14
NCT01447394: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Withdrawn
3
0
US, Canada, Europe, RoW
Pegylated Interferon Lambda, BMS-914143, Pegylated Interferon Alfa-2a, Pegasys, Ribavirin, Ribasphere
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
03/14
08/14
RESTORE, NCT01567735 / 2011-004097-29: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients

Checkmark Presented at BWG 2015
Mar 2015 - Mar 2015: Presented at BWG 2015
Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark AASLD 2014: RESTORE
More
Completed
3
107
Europe
TMC435
Janssen R&D Ireland
Hepatitis C
03/14
03/14
NCT01581398: Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Completed
3
770
RoW
Ypeginterferon alfa-2b, Pegasys
Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis C
04/14
06/14
NCT01471574 / 2011-003067-30: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed
3
549
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Ribavirin, Copegus®, PEG-Interferon alfa 2a, Pegasys®, Pegylated interferon
Bristol-Myers Squibb
Hepatitis C, Genotype 1
06/14
09/14
PRINCIPAL, NCT01616524 / 2011-004885-14: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed
3
880
Japan, US, Europe, RoW
Pegylated interferon lambda (pegIFNλ), BMS-914143, Pegylated interferon alfa-2a (pegIFNα-2a), Pegasys, Ribavirin, Ribasphere, Daclatasvir, BMS-790052, Placebo matching Daclatasvir
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
06/14
09/14
NCT01754974 / 2012-003508-11: Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Completed
3
40
Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Ribavirin, Ribasphere, Peginterferon alfa-2a, Pegasys
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
09/14
09/14
NCT01718158 / 2011-005409-65: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Completed
3
444
Japan, US, Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Peginterferon Alfa-2a, Pegasys®, Ribavirin, Copegus®, Daclatasvir, BMS-790052, Telaprevir, Incivek®
Bristol-Myers Squibb
Hepatitis C
10/14
10/14
NCT01544920 / 2011-001345-32: Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Completed
3
737
NA
peg-Interferon alfa-2a, Pegasys™; SCH 054031, Ribavirin, Rebetol™; 018908, Boceprevir, SCH 503034; Victrelis™
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
05/15
05/15
NCT01760122: Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Completed
3
820
RoW
Ypeginterferon alfa-2b, Pegasys
Xiamen Amoytop Biotech Co., Ltd., Peking University First Hospital
Chronic Hepatitis B
07/15
08/15
NCT01903278: Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Completed
3
719
RoW
PEG-IFN-SA /RBV, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis c
08/15
08/15
NCT01846832 / 2012-004905-29: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Checkmark Data from simeprevir + pegylated interferon alfa-2a + ribavirin 12-week triple combination, open-label, single-arm trial for treatment naïve GT1 hep C infected patients
Mar 2015 - Mar 2015: Data from simeprevir + pegylated interferon alfa-2a + ribavirin 12-week triple combination, open-label, single-arm trial for treatment naïve GT1 hep C infected patients
Completed
3
232
Europe, RoW
TMC435, Pegylated interferon alfa-2a (PegIFNα-2a), Pegasys, Ribavirin (RBV), Copegus
Janssen-Cilag International NV
Hepatitis C, Chronic, Infection
08/15
08/15
NCT01889433: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Completed
3
170
RoW
Algeron, Cepeginterferon alfa-2b, Pegasys, Peginterferon alfa-2a
Biocad
Hepatitis, Hepatitis C
12/15
12/15
MK-4031-376, NCT01641926: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Terminated
3
402
NA
PEG-Intron™, SCH 054031, Pegylated interferon alfa-2b, PEGASYS™, Pegylated interferon alfa-2a
Merck Sharp & Dohme LLC
Hepatitis B, Chronic
01/16
01/16
COMMAND-Asia, NCT01797848: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Withdrawn
3
0
RoW
Peginterferon alfa 2a, Pegasys®, Ribavirin, Copegus® (Taiwan, Korea and Singapore), Wei Lining (China), Placebo matching Daclatasvir, Daclatasvir, BMS-790052-05
Bristol-Myers Squibb
Hepatitis C
11/16
11/16
NCT01088659: A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Completed
3
50
RoW
peginterferon alfa-2a [Pegasys], placebo, tenofovir
Hoffmann-La Roche
Hepatitis D, Chronic
12/17
12/17
NCT01890200: The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Withdrawn
3
0
RoW
Peginterferon alfa-2a, Pegasys, Ribavirin, Rebetol, TCM-700C, Placebo, Placebo, without acting ingredient.
TCM Biotech International Corp.
Chronic Hepatitis C
03/18
06/18
HB01EMVIPEG, NCT00391638: Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Completed
2/3
56
Europe
TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a)
French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Roche Pharma AG
Hepatitis B, HIV Infections
05/11
10/12
No, NCT01006031 / 2009-009438-34: Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous nresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

Completed
2/3
25
Europe
Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus
Sociedad Andaluza de Enfermedades Infecciosas
Liver Cirrhosis, Hepatitis C Virus, HIV Infection
12/11
12/11
NCT01890772: Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

Withdrawn
2/3
0
US
Telaprevir, Incivek, Peginterferon alfa-2a, Pegasys, Ribavirin, Vitamin D
Timothy Morgan, MD, Vertex Pharmaceuticals Incorporated
Hepatitis C
10/15
 

Download Options